Appeal No. 1996-2216
Application No. 08/087,058
1. A method for the treatment of inflammatory skin disorders,
intestinal disorders or purpura which method comprises administering one
or more complement inhibitors from the group consisting of C1 inactivator,
factor I and factor H.
7. A method as claimed in claim 1, which comprises administering 1-
5000 IU/kg x day C1 inactivator, 0.005-100 mg/kg x day factor I, or 0.005-
100 mg/kg x day factor H.
The references relied on by the examiner are:
Pelzer et al. (Pelzer) 4,915,945 Apr. 10, 1990
Naka et al. (Naka) 4,981,855 Jan. 1, 1991
Sims et al. (Sims) 5,135,916 Aug. 4, 1992
Glover et al. (Glover) 5,157,019 Oct. 20, 1992
Lezdey et al. (Lezdey) 5,166,134 Nov. 24, 1992
Eur. Pat. App. (EP '611) 222 611 May 20, 1987
Kitano et al. (Kitano), "New Treatment of Ulcerative Colitis with K-76," Diseases of the
Colon & Rectum, Vol. 35, No. 6, pp. 560-67 (June 1992).
ISSUE3
Claims 1, 3, 5 and 7-9 stand rejected under 35 U.S.C. § 103 as being unpatentable
over EP '611, Kitano, Lezdey, Pelzer, Sims, Glover and Naka.
We REVERSE.
In reaching our decision in this appeal we have given careful consideration to the
appellants' specification and claims and to the respective positions articulated by the
According to the examiner, the final rejection of claims 1, 3, 5 and 7-9 under 35 U.S.C. § 112, first3
paragraph, for lack of enablement was overcome by the amendment filed January 13, 1995 (Paper No. 10)
(see the advisory action mailed February 1, 1995 (Paper No. 11)).
2
Page: Previous 1 2 3 4 5 6 7 8 Next
Last modified: November 3, 2007